{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:08:35Z","timestamp":1793606915765,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41388-017-0040-z","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T10:26:20Z","timestamp":1516962380000},"page":"2213-2224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma"],"prefix":"10.1038","volume":"37","author":[{"given":"Dima","family":"Ghannam-Shahbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reli Rachel","family":"Kakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Korsensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Sternfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora Rosa","family":"Bublik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Aviel-Ronen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-064X","authenticated-orcid":false,"given":"Keren","family":"Levanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Larisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Hershkovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Perets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"40_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451\u20136.","journal-title":"J Pathol"},{"key":"40_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","volume":"30","author":"F Medeiros","year":"2006","unstructured":"Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230\u20136.","journal-title":"Am J Surg Pathol"},{"key":"40_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/0008-5472.CAN-15-1382","volume":"76","author":"R Perets","year":"2015","unstructured":"Perets R, Drapkin R. It\u2019s totally tubular\u2026.riding the new wave of ovarian cancer research. Cancer Res. 2015;76:10\u20137.","journal-title":"Cancer Res"},{"key":"40_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ygyno.2006.08.052","volume":"104","author":"NJ Bowen","year":"2007","unstructured":"Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331\u20137.","journal-title":"Gynecol Oncol"},{"key":"40_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0168-9525(01)02594-X","volume":"18","author":"N Chi","year":"2002","unstructured":"Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2002;18:41\u20137.","journal-title":"Trends Genet"},{"key":"40_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/ng0598-87","volume":"19","author":"A Mansouri","year":"1998","unstructured":"Mansouri A, Chowdhury K, Gruss P. Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet. 1998;19:87\u201390.","journal-title":"Nat Genet."},{"key":"40_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1210\/en.2006-1054","volume":"148","author":"J Mittag","year":"2007","unstructured":"Mittag J, Winterhager E, Bauer K, Grummer R, Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology. 2007;148:719\u201325.","journal-title":"Endocrinology"},{"key":"40_CR8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0b013e3181da7687","volume":"34","author":"AR Laury","year":"2010","unstructured":"Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627\u201335.","journal-title":"Am J Surg Pathol"},{"key":"40_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/PAS.0b013e318216c112","volume":"35","author":"AR Laury","year":"2011","unstructured":"Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816\u201326.","journal-title":"Am J Surg Pathol"},{"key":"40_CR10","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1097\/PAS.0b013e31816d71ad","volume":"32","author":"D Nonaka","year":"2008","unstructured":"Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566\u201371.","journal-title":"Am J Surg Pathol."},{"key":"40_CR11","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1038\/onc.2011.190","volume":"30","author":"CG Li","year":"2011","unstructured":"Li CG, Nyman JE, Braithwaite AW, Eccles MR, PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein. Oncogene. 2011;30:4824\u201334.","journal-title":"Oncogene"},{"key":"40_CR12","doi-asserted-by":"publisher","first-page":"32785","DOI":"10.18632\/oncotarget.9051","volume":"7","author":"LH Rodgers","year":"2016","unstructured":"Rodgers LH, \u00d3 hAinmhire E, Young AN, Burdette JE, Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium. Oncotarget. 2016;7:32785\u201395.","journal-title":"Oncotarget"},{"key":"40_CR13","doi-asserted-by":"crossref","unstructured":"Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, et al. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI insight. 2016;1:e87988.","DOI":"10.1172\/jci.insight.87988"},{"issue":"4","key":"40_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/bjc.2016.426","volume":"116","author":"Siddhartha P Kar","year":"2017","unstructured":"Kar SP, Adler E, Tyrer J, Hazelett D, Anton-Culver H, Bandera EV, et al. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer. 2017;116:524\u201335. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28103614 . Accessed 14 Feb 2017.","journal-title":"British Journal of Cancer"},{"key":"40_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26\u201335.","journal-title":"J Pathol"},{"key":"40_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49\u201356.","journal-title":"J Pathol"},{"key":"40_CR17","doi-asserted-by":"crossref","unstructured":"TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315..","DOI":"10.1038\/nature10166"},{"key":"40_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","volume":"24","author":"R Perets","year":"2013","unstructured":"Perets R, Wyant G, Muto K, Bijron J, Poole B, Chin K, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten Models. Cancer Cell. 2013;24:751\u201365.","journal-title":"Cancer Cell"},{"key":"40_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.pgp.0000101082.35393.84","volume":"23","author":"ML Carcangiu","year":"2004","unstructured":"Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35\u201340.","journal-title":"Int J Gynecol Pathol."},{"key":"40_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/PAS.0b013e318282da7f","volume":"37","author":"JG Bijron","year":"2013","unstructured":"Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RHM, van Diest PJ. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37:1123\u201330.","journal-title":"Am J Surg Pathol"},{"key":"40_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.tcb.2011.10.006","volume":"22","author":"KT Bieging","year":"2012","unstructured":"Bieging KT, Attardi LD, Brady CA, Attardi LD, Vousden KH, Prives C, et al. Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol. 2012;22:97\u2013106.","journal-title":"Trends Cell Biol"},{"key":"40_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","volume":"119","author":"KP Olive","year":"2004","unstructured":"Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847\u201360.","journal-title":"Cell"},{"key":"40_CR23","doi-asserted-by":"publisher","first-page":"19257","DOI":"10.3390\/ijms140919257","volume":"14","author":"P Brachova","year":"2013","unstructured":"Brachova P, Thiel KW, Leslie KK. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci. 2013;14:19257\u201375.","journal-title":"Int J Mol Sci"},{"key":"40_CR24","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/ijc.29528","volume":"137","author":"SM Quartuccio","year":"2015","unstructured":"Quartuccio SM, Karthikeyan S, Eddie SL, Lantvit DD, \u00d3 hAinmhire E, Modi DA, et al. Mutant p53 expression in fallopian tube epithelium drives cell migration. Int J Cancer. 2015;137:1528\u201338.","journal-title":"Int J Cancer"},{"key":"40_CR25","doi-asserted-by":"crossref","unstructured":"Iwanicki MP, Chen H-Y, Iavarone C, Zervantonakis IK, Muranen T, Novak M, et al. Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI insight. 2016;1:e86829.","DOI":"10.1172\/jci.insight.86829"},{"key":"40_CR26","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1002\/j.1460-2075.1995.tb00251.x","volume":"14","author":"ET Stuart","year":"1995","unstructured":"Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 1995;14:5638\u201345.","journal-title":"EMBO J"},{"key":"40_CR27","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1038\/onc.2011.511","volume":"31","author":"X Li","year":"2012","unstructured":"Li X, Cheung KF, Ma X, Tian L, Zhao J, Go MYY, et al. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene. 2012;31:3419\u201330.","journal-title":"Oncogene"},{"key":"40_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","volume":"75","author":"WS El-Deiry","year":"1993","unstructured":"El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817\u201325.","journal-title":"Cell"},{"key":"40_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ygyno.2012.06.012","volume":"127","author":"P Mhawech-Fauceglia","year":"2012","unstructured":"Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Ough F, Liu S, et al. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Gynecol Oncol. 2012;127:198\u2013201.","journal-title":"Gynecol Oncol"},{"key":"40_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/PAP.0b013e318253465d","volume":"19","author":"NG Ordonez","year":"2012","unstructured":"Ordonez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012;19:140\u201351.","journal-title":"Adv Anat Pathol"},{"key":"40_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.","journal-title":"Nat Commun"},{"key":"40_CR32","doi-asserted-by":"publisher","first-page":"12372","DOI":"10.1073\/pnas.1109363108","volume":"108","author":"HW Cheung","year":"2011","unstructured":"Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA. 2011;108:12372\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"40_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"40_CR34","first-page":"4196","volume":"52","author":"Y Yaginuma","year":"1992","unstructured":"Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 1992;52:4196\u20139.","journal-title":"Cancer Res."},{"key":"40_CR35","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/onc.2015.288","volume":"35","author":"G Hua","year":"2016","unstructured":"Hua G, Lv X, He C, Remmenga SW, Rodabough KJ, Dong J, et al. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene. 2016;35:2247","journal-title":"Oncogene"},{"key":"40_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","volume":"75","author":"JW Harper","year":"1993","unstructured":"Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805\u201316.","journal-title":"Cell"},{"key":"40_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1091\/mbc.e07-06-0525","volume":"19","author":"A Satyanarayana","year":"2008","unstructured":"Satyanarayana A, Hilton MB, Kaldis P. p21 inhibits Cdk1 in the absence of Cdk2 to maintain the G1\/S phase DNA damage checkpoint. Mol Biol Cell. 2008;19:65\u201377.","journal-title":"Mol Biol Cell"},{"key":"40_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.onc.1201543","volume":"16","author":"C Cayrol","year":"1998","unstructured":"Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998;16:311\u201320.","journal-title":"Oncogene"},{"key":"40_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas T, Dutta A, p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400\u201314.","journal-title":"Nat Rev Cancer"},{"key":"40_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/35060032","volume":"3","author":"BP Zhou","year":"2001","unstructured":"Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1\/WAF1 by Akt-induced phosphorylation in HER-2\/neu-overexpressing cells. Nat Cell Biol. 2001;3:245\u201352.","journal-title":"Nat Cell Biol"},{"key":"40_CR41","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/emboj\/18.5.1223","volume":"18","author":"M Asada","year":"1999","unstructured":"Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, et al. Apoptosis inhibitory activity of cytoplasmicp21(Cip1\/WAF1) in monocytic differentiation. EMBO J. 1999;18:1223\u201334.","journal-title":"EMBO J."},{"key":"40_CR42","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1074\/jbc.M306968200","volume":"279","author":"S Lee","year":"2004","unstructured":"Lee S, Helfman DM. Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK\/LIMK\/cofilin pathway. J Biol Chem. 2004;279:1885\u201391.","journal-title":"J Biol Chem"},{"key":"40_CR43","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2016","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2016;36:1461\u201373.","journal-title":"Oncogene"},{"key":"40_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12015-016-9691-3","volume":"13","author":"O Oren","year":"2016","unstructured":"Oren O, Smith BD. Eliminating cancer stem cells by targeting embryonic signaling pathways. Stem Cell Rev. 2016;13:17\u201323.","journal-title":"Stem Cell Rev"},{"key":"40_CR45","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/onc.2016.307","volume":"36","author":"DW Chan","year":"2016","unstructured":"Chan DW, Hui WWY, Wang JJ, Yung MMH, Hui LMN, Qin Y, et al. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-\u03b2\/SMAD4 signaling. Oncogene. 2016;36:1404\u201316.","journal-title":"Oncogene"},{"key":"40_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1242\/dev.091785","volume":"141","author":"JA Blake","year":"2014","unstructured":"Blake JA, Ziman MR.Pax genes: regulators of lineage specification and progenitor cell maintenance. Development. 2014;141:737\u201351.","journal-title":"Development"},{"key":"40_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1677\/JOE-06-0054","volume":"192","author":"J Wistuba","year":"2007","unstructured":"Wistuba J, Mittag J, Luetjens CM, Cooper TG, Yeung C-H, Nieschlag E, et al. Male congenital hypothyroid Pax8-\/- mice are infertile despite adequate treatment with thyroid hormone. J Endocrinol. 2007;192:99\u2013109.","journal-title":"J Endocrinol."},{"key":"40_CR48","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/modpathol.2009.92","volume":"22","author":"CS Tung","year":"2009","unstructured":"Tung CS, Mok SC, Tsang YTM, Zu Z, Song H, Liu J, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009;22:1243\u201350.","journal-title":"Mod Pathol."},{"key":"40_CR49","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/1940-6207.CAPR-15-0121-T","volume":"8","author":"EM Al-Hujaily","year":"2015","unstructured":"Al-Hujaily EM, Tang Y, Yao D-S, Carmona E, Garson K, Vanderhyden BC Divergent roles of PAX2 in the etiology and progression of ovarian cancer. Cancer Prev Res. 2015;8:1163\u201373.","journal-title":"Cancer Prev Res."},{"key":"40_CR50","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/ng.2754","volume":"45","author":"S Shah","year":"2013","unstructured":"Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226\u201331.","journal-title":"Nat Genet"},{"key":"40_CR51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/hep.24124","volume":"53","author":"W Liu","year":"2011","unstructured":"Liu W, Li X, Chu ESH, Go MYY, Xu L, Zhao G, et al. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology. 2011;53:843\u201353.","journal-title":"Hepatology"},{"key":"40_CR52","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1210\/en.2005-0147","volume":"147","author":"AY Au","year":"2006","unstructured":"Au AY, McBride C, Wilhelm KG,Jr, Koenig RJ, Speller B, Cheung L, et al. PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology. 2006;147:367\u201376.","journal-title":"Endocrinology"},{"key":"40_CR53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/dc.21426","volume":"39","author":"GX Tong","year":"2011","unstructured":"Tong GX, Devaraj K, Hamele-Bena D, Yu WM, Turk A, Chen X. et al. Pax8: a marker of carcinoma of M\u00fcllerian origin in serous effusions. Diagn Cytopathol. 2011;39:567\u201374.","journal-title":"Diagn Cytopathol"},{"key":"40_CR54","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"40_CR55","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2617","volume":"45","author":"K Chang","year":"2013","unstructured":"Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113\u201320.","journal-title":"Nat Genet"},{"issue":"3","key":"40_CR56","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/carcin\/bgq249","volume":"32","author":"K. Doberstein","year":"2010","unstructured":"Doberstein K, Wieland A, Lee SBB, Blaheta RAA, Wedel S, Moch H, et al. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis. 2011;32:262\u201370. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21097529 . Accessed 1 Mar 2011.","journal-title":"Carcinogenesis"},{"key":"40_CR57","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/j.1460-2075.1996.tb00418.x","volume":"15","author":"S Rowan","year":"1996","unstructured":"Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 1996;15:827\u201338.","journal-title":"EMBO J"},{"key":"40_CR58","first-page":"662","volume":"36","author":"X Xia","year":"2015","unstructured":"Xia X, Ji T, Liu R, Weng Y, Fang Y, Wang Z, et al. Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells. Eur J Gynaecol Oncol. 2015;36:662\u20136.","journal-title":"Eur J Gynaecol Oncol."},{"key":"40_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046467","volume":"7","author":"R Perets","year":"2012","unstructured":"Perets R, Kaplan T, Stein I, Hidas G, Tayeb S, Avraham E, et al. Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer. PLoS ONE. 2012;7:e46467.","journal-title":"PLoS ONE."},{"key":"40_CR60","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nprot.2013.023","volume":"8","author":"R Blecher-Gonen","year":"2013","unstructured":"Blecher-Gonen R, Barnett-Itzhaki Z, Jaitin D, Amann-Zalcenstein D, Lara-Astiaso D, Amit I. High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. Nat Protoc. 2013;8:539\u201354.","journal-title":"Nat Protoc."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-017-0040-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-017-0040-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-017-0040-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:09:50Z","timestamp":1684616990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-017-0040-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":60,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1038\/s41388-017-0040-z","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"11 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}